DUBLIN – Shares in Innate Pharma SA rose by as much as 39 percent during trading Tuesday as the French biotech and its partner, Astrazeneca plc, rejigged their existing oncology alliance, which now guarantees a minimum $241.85 million in cash to Innate, with the potential for a whole lot more – almost $5.2 billion – to come in option fees and milestone payments.